학술논문
Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period
Document Type
Article
Author
Source
In: Diabetes, Obesity and Metabolism . (Diabetes, Obesity and Metabolism, May 2022, 24(5):838-848)
Subject
Language
English
ISSN
14631326
14628902
14628902